Cellectis SA (CLLS) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $4.02
• Market Cap: $420.47M
• EPS: $-0.33
• 52-Week High: $5.48
• 52-Week Low: $1.10

Market Sentiment

Cellectis SA currently has a Neutral sentiment score of 0.03.

About Cellectis SA

Cellectis SA is a clinical-stage biotechnology firm headquartered in Paris, France, specializing in the development of innovative immuno-oncology therapies utilizing its proprietary gene-editing platform. By leveraging its cutting-edge technology, the company creates T cell therapies that incorporate chimeric antigen receptors (CARs) to effectively target and eliminate cancer cells. With a diverse pipeline of candidates at various clinical development stages and strategic partnerships, Cellec...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Cellectis SA and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CLLS pay dividends?

Cellectis SA (CLLS) does not currently pay a regular dividend.

What is CLLS's market cap?

Cellectis SA (CLLS) has a market capitalization of $420.47M with a current stock price of $4.02.